ROLE OF ANDROGEN RECEPTOR-TARGETED AGENTS IN LOCALIZED PROSTATE CANCER

Overview

Journal Acta Clin Croat

Specialty General Medicine

Date 2023 Mar 20

PMID 36938555

Authors

Jure Murgic

Ana Frobe

Amarnath Challapalli

Amit Bahl

Affiliations

Soon will be listed here.

Abstract

Anti-androgen therapy continues to be a basic pilar of treatment for both localized and metastatic prostate cancer. The advent of new generation of androgen receptor targeted agents (ARTA) transformed the care of patients with advanced disease. After such a success, the steps were taken to incorporate a new generation of ARTAs into the treatment landscape of localized prostate cancer. High-risk prostate cancer represents the most aggressive form of localized disease with significant metastatic potential and poor outcome. Here, the impact of novel therapies will likely be profound and transforming. This clinical space has already been a showcase for multidisciplinary treatment where the combination of local therapies with systemic treatment gradually improved patient outcomes and the chances of cure. The most recent step in redefining the treatment of localized disease is the adoption of novel ARTAs moving forward the multidisciplinary platform. In this narrative review, we discuss current clinical evidence supporting the use of novel ARTAs in patients with localized high-risk prostate cancer and cover recent developments in biomarker-driven strategies for treatment individualization in this clinical context.

References

Attard G, Brown L, Clarke N, Parmar M, James N . Should Patients with High-risk Localised or Locally Advanced Prostate Cancer Receive Abiraterone Acetate in Addition to Androgen Deprivation Therapy? Update on a Planned Analysis of the STAMPEDE Trial. Eur Urol. 2021; 80(4):522-523. DOI: 10.1016/j.eururo.2021.06.023. View

Crawford E, Heidenreich A, Lawrentschuk N, Tombal B, Pompeo A, Mendoza-Valdes A . Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations. Prostate Cancer Prostatic Dis. 2018; 22(1):24-38. PMC: 6370592. DOI: 10.1038/s41391-018-0079-0. View

Zong Y, Goldstein A . Adaptation or selection--mechanisms of castration-resistant prostate cancer. Nat Rev Urol. 2012; 10(2):90-8. DOI: 10.1038/nrurol.2012.237. View

Albertsen P, Hanley J, Fine J . 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA. 2005; 293(17):2095-101. DOI: 10.1001/jama.293.17.2095. View

Kane C, Presti Jr J, Amling C, Aronson W, Terris M, Freedland S . Changing nature of high risk patients undergoing radical prostatectomy. J Urol. 2006; 177(1):113-7. DOI: 10.1016/j.juro.2006.08.057. View

de Bono J, Logothetis C, Molina A, Fizazi K, North S, Chu L . Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011; 364(21):1995-2005. PMC: 3471149. DOI: 10.1056/NEJMoa1014618. View

Zapatero A, Guerrero A, Maldonado X, Alvarez A, Gonzalez San Segundo C, Cabeza Rodriguez M . High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial. Lancet Oncol. 2015; 16(3):320-7. DOI: 10.1016/S1470-2045(15)70045-8. View

Pagliarulo V, Bracarda S, Eisenberger M, Mottet N, Schroder F, Sternberg C . Contemporary role of androgen deprivation therapy for prostate cancer. Eur Urol. 2011; 61(1):11-25. PMC: 3483081. DOI: 10.1016/j.eururo.2011.08.026. View

Smith M, Hussain M, Saad F, Fizazi K, Sternberg C, Crawford E . Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. N Engl J Med. 2022; 386(12):1132-1142. PMC: 9844551. DOI: 10.1056/NEJMoa2119115. View

10.

McKay R, Montgomery B, Xie W, Zhang Z, Bubley G, Lin D . Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade. Prostate Cancer Prostatic Dis. 2017; 21(3):364-372. PMC: 6013399. DOI: 10.1038/s41391-017-0009-6. View

11.

McKay R, Feng F, Wang A, Wallis C, Moses K . Recent Advances in the Management of High-Risk Localized Prostate Cancer: Local Therapy, Systemic Therapy, and Biomarkers to Guide Treatment Decisions. Am Soc Clin Oncol Educ Book. 2020; 40:1-12. PMC: 10182417. DOI: 10.1200/EDBK_279459. View

12.

Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev B . Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med. 2017; 377(4):352-360. DOI: 10.1056/NEJMoa1704174. View

13.

Bolla M, Collette L, Blank L, Warde P, Dubois J, Mirimanoff R . Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002; 360(9327):103-6. DOI: 10.1016/s0140-6736(02)09408-4. View

14.

Hofman M, Lawrentschuk N, Francis R, Tang C, Vela I, Thomas P . Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020; 395(10231):1208-1216. DOI: 10.1016/S0140-6736(20)30314-7. View

15.

Spratt D, Yousefi K, Deheshi S, Ross A, Den R, Schaeffer E . Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease. J Clin Oncol. 2017; 35(18):1991-1998. PMC: 6530581. DOI: 10.1200/JCO.2016.70.2811. View

16.

Taplin M, Montgomery B, Logothetis C, Bubley G, Richie J, Dalkin B . Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. J Clin Oncol. 2014; 32(33):3705-15. PMC: 4226804. DOI: 10.1200/JCO.2013.53.4578. View

17.

Raj-Kumar P, Liu J, Hooke J, Kovatich A, Kvecher L, Shriver C . PCA-PAM50 improves consistency between breast cancer intrinsic and clinical subtyping reclassifying a subset of luminal A tumors as luminal B. Sci Rep. 2019; 9(1):7956. PMC: 6538748. DOI: 10.1038/s41598-019-44339-4. View

18.

Cooperberg M, Broering J, Carroll P . Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol. 2010; 28(7):1117-23. PMC: 2834465. DOI: 10.1200/JCO.2009.26.0133. View

19.

Rosenthal S, Hunt D, Sartor A, Pienta K, Gomella L, Grignon D . A Phase 3 Trial of 2 Years of Androgen Suppression and Radiation Therapy With or Without Adjuvant Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902. Int J Radiat Oncol Biol Phys. 2015; 93(2):294-302. PMC: 4719152. DOI: 10.1016/j.ijrobp.2015.05.024. View

20.

Nguyen P, Haddad Z, Ross A, Martin N, Deheshi S, Lam L . Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens. Eur Urol. 2017; 72(5):845-852. DOI: 10.1016/j.eururo.2017.05.009. View